Severe and long-lasting alteration of albumin redox state by plasmapheresis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 07 2022
16 07 2022
Historique:
received:
23
01
2022
accepted:
11
07
2022
entrez:
16
7
2022
pubmed:
17
7
2022
medline:
20
7
2022
Statut:
epublish
Résumé
Plasmapheresis (PE) is an established form of therapeutic apheresis (TA). Purpose of this longitudinal prospective single center study was to investigate the effect of PE on albumin redox state (ARS), as infusion of commercial albumin during PE may alter albumin oxidation which has an impact on its functional properties and oxidative stress level. 43 subjects with autoimmune-mediated neurological disorders were included. 20 subjects in the experimental group received five treatments of PE. 13 subjects received five treatments of immunoadsorption and 10 subjects received no TA as controls. ARS was determined before and after TA and 12 days after the last TA by fractionating it into human mercaptalbumin (HMA), human non-mercaptalbumin 1 (HNA-1), and human non-mercaptalbumin 2 (HNA-2) by high-performance liquid chromatography. Irreversibly oxidised HNA-2 increased over the course of five PE treatments from 2.8% (IQR 1.3-3.7%) to 13.6% (IQR 10.9-15.9) (P < 0.01) and remained elevated 12 days after the last PE procedure (7.7% IQR 7.1-10.5, P < 0.05). The study showed for the first time that PE exerts a severe and long-lasting alteration on ARS indicating a new adverse effect of PE, that may influence oxidative stress level.
Identifiants
pubmed: 35842435
doi: 10.1038/s41598-022-16452-4
pii: 10.1038/s41598-022-16452-4
pmc: PMC9288533
doi:
Substances chimiques
Serum Albumin, Human
ZIF514RVZR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12165Informations de copyright
© 2022. The Author(s).
Références
Mol Aspects Med. 2012 Jun;33(3):209-90
pubmed: 22230555
J Pharm Sci. 2022 May;111(5):1292-1308
pubmed: 35276228
Sci Rep. 2020 May 13;10(1):7925
pubmed: 32404917
Mol Neurobiol. 2017 May;54(4):2961-2968
pubmed: 27026183
Nat Rev Neurol. 2017 Oct;13(10):599-611
pubmed: 28914883
Front Neurosci. 2020 Aug 26;14:823
pubmed: 32982663
Free Radic Res. 2008 Jul;42(7):633-8
pubmed: 18654878
J Hepatol. 2013 Nov;59(5):978-83
pubmed: 23811308
EClinicalMedicine. 2019 Nov 14;16:98-106
pubmed: 31832624
Kidney Int. 2013 Sep;84(3):622-3
pubmed: 23989362
Aliment Pharmacol Ther. 2005 Dec;22(11-12):1079-89
pubmed: 16305721
J Clin Apher. 2019 Aug;34(4):381-391
pubmed: 30698295
Antioxid Redox Signal. 2012 Dec 1;17(11):1515-27
pubmed: 22587567
Front Neurol. 2021 Oct 13;12:714631
pubmed: 34721257
J Crit Care. 2016 Oct;35:161-7
pubmed: 27481753
J Alzheimers Dis. 2018;63(4):1395-1404
pubmed: 29782326
Gastroenterology. 1989 Aug;97(2):439-45
pubmed: 2490426
Intensive Care Med. 2010 Oct;36(10):1657-1665
pubmed: 20517593
BMC Neurol. 2016 Apr 12;16:47
pubmed: 27067000
Clin Rheumatol. 2020 Dec;39(12):3581-3592
pubmed: 32468321
Antioxidants (Basel). 2021 Mar 08;10(3):
pubmed: 33800425
Biologicals. 2020 Mar;64:41-48
pubmed: 31980347
Methods Enzymol. 2010;474:181-95
pubmed: 20609911
J Clin Apher. 2019 Jun;34(3):171-354
pubmed: 31180581
FEBS Lett. 2008 Jun 11;582(13):1783-7
pubmed: 18474236
Gut. 2020 Jun;69(6):1127-1138
pubmed: 32102926
Ther Apher Dial. 2009 Oct;13(5):431-6
pubmed: 19788461
J Clin Apher. 2009;24(6):225-31
pubmed: 19890911
J Clin Med. 2020 Jun 27;9(7):
pubmed: 32605107